XTL BiopharmaceuticalsXTLB
13F holders, Q1 2024 (March 31)5holders
1famous investor
$2.81avg. 13F price*
At the end of Q1 2024, 5 institutions reported holding XTL Biopharmaceuticals Ltd. (XTLB) in their 13F filings. The largest holders were Noked Israel Ltd ($559K), Morgan Stanley ($110K) and Citadel Advisors ($38K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- XTL Biopharmaceuticals Ltd.
- CUSIP
- 98386D307
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $38K |
| Exits | 1 | $203 |
Ownership 5 holders
| Noked Israel Ltd | 0.15% | No change | 198,888 | $559K |
| Morgan Stanley | 0.00% | Reduce -1.5% | 39,171 | $110K |
| Citadel Advisors | 0.00% | New | 13,631 | $38K |
| UBS Group AG | 0.00% | Add +12777.8% | 6,954 | $20K |
| BNP Paribas Financial Markets | 0.00% | No change | 300 | $843 |
"% of holder's portfolio" is XTLB's weight in each manager's 13F, not the share of XTL Biopharmaceuticals Ltd. the manager owns.